Early detection of safety liabilities of new therapies is a critical biopharmaceutical challenge. Addressing this challenge could significantly advance drug discovery. Advanced human cell models, ...

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell ...

X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain.

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part ...

Peripheral neuropathy (PN) is a dose-limiting side effect of chemotherapeutic and antibody drug conjugate (ADC) treatment which significantly impacts patients’ quality of life. Despite a high clinical ...

New confocal fluorescence imaging minimizes photobleaching and phototoxicity effects, capturing clear images of live 3D culture Industry-leading throughput enables real-time analysis of up to six ...

In this whitepaper, Sartorius discusses the need to replace animal testing with advanced in vitro human cell models for pharmaceutical, chemical, and cosmetic development as, with only 5-10% of ...

NEWCASTLE, England--(BUSINESS WIRE)--Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it ...